Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Advances NXP900 Phase 1b and Reports Q1 2026 Results

Nuvectis Pharma reported its first-quarter 2026 financial results and provided an update on its NXP900 clinical program. The company is actively enrolling patients in the Phase 1b study for NXP900 in both monotherapy and combination arms across US sites. Preclinical data presented at the 2026 AACR Annual Meeting demonstrated synergy for NXP900 in combination with sotorasib in non-small cell lung cancer models. Nuvectis anticipates a preliminary data readout from the NXP900 Phase 1b study in the summer of 2026. Financially, cash and cash equivalents stood at $25.1 million as of March 31, 2026, with a net loss of $6.1 million for the quarter.

• Nuvectis Pharma is actively advancing its NXP900 Phase 1b clinical program, with patient enrollment continuing at top sites across the U.S. The study includes both monotherapy and combination arms, reflecting a comprehensive approach to evaluating NXP900, an oral small molecule inhibitor of the SRC Family of Kinases (SFK), for serious conditions in oncology.
• At the 2026 American Association for Cancer Research (AACR) Annual Meeting, Nuvectis presented preclinical data for NXP900. These findings highlighted clear synergy when NXP900 was combined with sotorasib, a RAS inhibitor, in both sotorasib-sensitive and sotorasib-resistant non-small cell lung cancer (NSCLC) models, further supporting its clinical development strategy.
• For the first quarter ended March 31, 2026, Nuvectis reported cash and cash equivalents of $25.1 million, a decrease from $31.6 million at the end of 2025. The company's net loss for the quarter was $6.1 million, an increase from $5.3 million in the prior year period, primarily driven by increased research and development and general and administrative expenses.
• Nuvectis expects a significant milestone in the summer of 2026 with a preliminary data readout from the ongoing NXP900 Phase 1b study. The company emphasized its commitment to financial discipline and achieving key clinical development milestones for the NXP900 program throughout 2026 and beyond, aiming to address unmet medical needs in oncology.

NXP900's Synergistic Combination Strategy in NSCLC

Recent NSCLC clinical trials are exploring diverse combination strategies targeting multiple pathways to improve patient outcomes. These approaches span immune checkpoint inhibitor combinations, targeted therapy pairings, and novel drug conjugates. Current investigations demonstrate promising synergistic effects across various treatment modalities.

• Tiragolumab plus PD-1/PD-L1 inhibitors showed improved objective response rates (37% vs. 21% with PD-L1 monotherapy) and progression-free survival in the CITYSCAPE trial, with TIGIT blockade reducing CD155-mediated suppression and enhancing cytotoxic T lymphocyte activity

• Tislelizumab plus chemotherapy (paclitaxel/carboplatin or nab-paclitaxel/carboplatin) for first-line squamous NSCLC demonstrated median OS of 26.1 months and 23.3 months respectively versus 19.4 months for chemotherapy alone, with 4-year OS rates of 32.2%, 26.0%, and 19.2%

• Immune checkpoint inhibitors combined with chemotherapy as first-line treatment for advanced NSCLC with bone metastases achieved bone metastasis response rate of 43.4% versus 20.5% for ICI monotherapy, with median OS of 20.7 months versus 16.0 months

• Datopotamab deruxtecan plus rilvegostomig (TROP2-directed ADC plus bispecific anti-PD-1/anti-TIGIT antibody) is being evaluated against pembrolizumab in the phase 3 TROPION-Lung10 trial for first-line treatment of advanced nonsquamous NSCLC with PD-L1 TC ≥50%

• EGFR-TKI plus platinum-based chemotherapy in EGFR-mutant patients with liver metastases achieved higher objective response rate (59.0% vs 35.6%) and longer median PFS (14.0 vs 10.4 months) compared to monotherapy

• Consolidative stereotactic radiotherapy plus maintenance chemoimmunotherapy in metastatic driver mutation-negative NSCLC with oligo-residual disease achieved median PFS of 29.0 months with 2-year OS rate of 88.9% in phase 2 trials

• Triple-combination immunotherapy comprising PD-1 antibody, adoptive NK cells, and oncolytic adenovirus Ad-anti-TGF-βRII markedly inhibited tumor growth and augmented NK cell cytotoxicity in preclinical NSCLC xenograft models

Evolving NSCLC Treatment Landscape: Where NXP900 Could Fit

The NSCLC treatment landscape has undergone fundamental transformation over the past five years, driven by the emergence of immunotherapy as an epoch-defining treatment modality with improved curative effects, prognosis, and tolerability compared to traditional cytotoxic chemotherapy. Real-world studies demonstrate that chemotherapy use has declined over time, being systematically replaced by immunotherapy, while molecular targeted therapy has shown relative stability. This shift has resulted in measurable clinical benefits, with survival at 18 months after diagnosis increasing in patients with advanced stages, coinciding with the widespread adoption of immunotherapy approaches.

Perioperative immunotherapy has evolved to encompass multiple strategic approaches, including neoadjuvant immune checkpoint inhibitor monotherapy, neoadjuvant immune-combination therapy (chemoimmunotherapy, immunotherapy plus antiangiogenic therapy, immunotherapy plus radiotherapy), adjuvant immunotherapy, and neoadjuvant combined adjuvant immunotherapy. Landmark Phase 3 studies IMpower 010 and CheckMate 816 have reported significant survival benefits of perioperative immunotherapy for operable patients. Additionally, PD-1 rechallenge strategies combining PD-1 inhibitors with chemotherapy or anlotinib have demonstrated measurable antitumor activity in previously immunotherapy-treated patients, with objective response rates of 30.3% and 22.6% respectively, substantially outperforming docetaxel monotherapy.

The targeted therapy landscape has experienced remarkable expansion, particularly with seven new FDA approvals in 2025 alone across multiple molecular targets, including MET-directed and TROP-2 antibody-drug conjugates, expanded EGFR strategies addressing exon 20 insertion mutations, ROS1 inhibitors, and HER2-directed approaches. Tyrosine kinase inhibitors have emerged as increasingly attractive targeted therapy options, with significant advances in ALK-positive NSCLC through multiple generations of inhibitors, from first-generation crizotinib to fourth-generation agents like repotrectinib. However, these therapeutic advances have introduced new challenges, including TKI resistance mechanisms and adverse cardiovascular effects, while combination approaches such as sintilimab plus anlotinib have shown superior efficacy with objective response rates of 44.9% versus 18.0% for chemotherapy in first-line metastatic NSCLC treatment.

NXP900: A Versatile Strategy Against Resistant Cancers

Nuvectis Pharma's NXP900 is emerging as a compelling candidate in precision oncology, particularly for cancers where existing therapies face significant resistance challenges. As a novel Src family kinase (SFK) 'OFF' inhibitor, NXP900 demonstrates remarkable preclinical synergy across multiple difficult-to-treat indications. For patients with RET fusion-positive non-small cell lung cancer (NSCLC) and papillary thyroid carcinoma (PTC), NXP900's ability to enhance the efficacy of RET TKIs and, crucially, restore sensitivity in selpercatinib-resistant cells, offers a potential breakthrough. This mechanism directly addresses a major limitation of targeted therapies: acquired resistance.

Beyond RET fusions, NXP900 shows promise in cholangiocarcinoma (CCA), a highly aggressive cancer with limited treatment options. Here, it acts as a novel YAP inhibitor, demonstrating efficacy in preclinical models and synergizing with standard chemotherapy. The particular sensitivity observed in IDH-mutant CCA models highlights a potential path for biomarker-driven development, allowing for more targeted patient selection. Furthermore, preclinical data suggesting synergy with sotorasib in NSCLC models hints at a broader applicability for NXP900 in other oncogene-driven NSCLC contexts.

The upcoming preliminary data readout from the Phase 1b study in summer 2026 will be a pivotal moment, providing the first human clinical insights into NXP900's safety and efficacy. While the preclinical data is robust, the transition to clinical validation always carries inherent risks. The company's current financial runway also warrants consideration as the program progresses through more extensive and costly trials. Moreover, while NXP900 tackles resistance to other drugs, studies indicate that resistance to SFK-YAP inhibition itself can emerge, suggesting that future combination strategies might be necessary to maintain long-term efficacy. Nevertheless, NXP900's multifaceted potential to overcome resistance and target aggressive cancers positions it as a significant asset to watch in the evolving oncology landscape.